Zobrazeno 31 - 40
of 169
pro vyhledávání: ''
Autor:
Sornchai Looareesuwan, Sanjeev Krishna, François Nosten, L Phaipun, Ken Laing, Ric N. Price, Anne-Catrin Uhlemann, Alan Brockman, Elizabeth A. Ashley, Rose McGready, Rina Patel, Nicholas J. White
Publikováno v:
The Lancet. 364:438-447
BACKGROUND: The borders of Thailand harbour the world's most multidrug resistant Plasmodium falciparum parasites. In 1984 mefloquine was introduced as treatment for uncomplicated falciparum malaria, but substantial resistance developed within 6 years
Autor:
Karen I. Barnes, Francesca Little, H Mcllleron, James Mwenechanya, Madalitso Tembo, M Gomes, Malcolm E. Molyneux, Peter I. Folb, I Ribeiro
Publikováno v:
The Lancet. 363:1598-1605
Many patients with malaria of increasing severity cannot take medicines orally, and delay in injectable treatment can be fatal. We aimed to assess the reliability of absorption, antimalarial efficacy, and tolerability of a single rectal dose of artes
Publikováno v:
The Lancet. 362:2095-2100
More than 170 million people worldwide are chronically infected with the hepatitis C virus (HCV), which is responsible for more than 100000 cases of liver cancer per year, with similar numbers of digestive haemorrhage and ascites episodes. Major brea
Autor:
Masyuki Takada, Ashio Yoshimura, Naoyuki Nakao, Hiroyuki Morita, Tsuguo Kayano, Terukuni Ideura
Publikováno v:
The Lancet. 361:117-124
Summary Background Present angiotensin-converting-enzyme inhibitor treatment fails to prevent progression of non-diabetic renal disease. We aimed to assess the efficacy and safety of combined treatment of angiotensin-converting-enzyme inhibitor and a
Autor:
P. Aylward, Anthony C Keech, Andrew Tonkin, David Colquhoun, Stephen MacMahon, Wendy Hague, David M. Hunt, Paul Glasziou, Adrienne Kirby, R. J. Simes
Publikováno v:
The Lancet. 359:1379-1387
BACKGROUND: The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study showed that pravastatin therapy over 6 years reduced mortality and cardiovascular events in patients with previous acute coronary syndromes and average cholest
Autor:
Elizabeth Hills, Theonest K. Mutabingwa, E.K. Mberu, Peter Winstanley, William M. Watkins, Eunice Nduati, Alexis Nzila
Publikováno v:
The Lancet. 358:1218-1223
Summary Background Resistance to the affordable malaria treatments chloroquine and pyrimethamine-sulfadoxine is seriously impeding malaria control through treatment in east Africa. We did an open, alternate drug allocation study to assess the efficac
Autor:
Ferrari, Lee A. Phebus, Kirk W. Johnson, JM Schaus, DJ Goldstein, NM Ramadan, Krista I. Roon, WW Offen
Publikováno v:
The Lancet. 358:1230-1234
Triptans (5-HT(1B/1D) receptor agonists) are effective drugs for acute migraine, but the side-effect of coronary vasoconstriction restricts their use in patients who are at risk of coronary artery disease. We have studied the efficacy of LY334370, a
Autor:
Vinod K. Rustgi, Michael P. Manns, Zachary Goodman, Robert Reindollar, Kenneth Koury, Mei Hsiu Ling, Janice K. Albrecht, Stuart C. Gordon, Mitchell L. Shiffman, John G. McHutchison
Publikováno v:
The Lancet. 358:958-965
Summary Background A sustained virological response (SVR) rate of 41% has been achieved with interferon alfa-2b plus ribavirin therapy of chronic hepatitis C. In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon
Autor:
Nguyen Thi Nhu Ngoc, A Metin Gülmezoglu, Alain Pinol, Guillermo Carroli, Diana Elbourne, Walter Prendiville, Christian Unger, Kenneth F. Schulz, José Villar, Lekan Adetoro, Gilda Piaggio, G Justus Hofmeyr, Pisake Lumbiganon, Hazem El-Refaey, Linan Cheng, Hany Abdel-Aleem
Publikováno v:
The Lancet. 358:689-695
Postpartum haemorrhage is a leading cause of maternal morbidity and mortality. Active management of the third stage of labour, including use of a uterotonic agent, has been shown to reduce blood loss. Misoprostol (a prostaglandin E1 analogue) has bee
Publikováno v:
The Lancet. 357:101-105
Summary Background The concentrations of fibrinogen, factor VII and VIII, von Willebrand factor, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator have been associated with coronary-heart disease. In addition, polymorphisms